27.04.2022 / Deals & Cases

Deal: NLS Pharmaceutics closes of a USD 4.4m registered direct offering

NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced the purchase of and sale of USD 4.2m common shares (or common share equivalents) at a purchase price of USD 1.04m per common share in a registered direct offering priced at-the-market under Nasdaq rules with gross proceeds of USD 4.4m.

The company intends to use the net proceeds from this offering, together with its existing cash, to fund the ongoing development of its lead product, Quilience® (Mazindol ER) for the treatment of narcolepsy, to support business development and licensing activities, and for general corporate purposes.

We advised NLS Pharmaceutics on all Swiss legal aspects.

Our team was led by Pascal Honold (Partner, M&A) and included Andreas Hünerwadel (Partner, Financial Services), Alessa Waibel (Associate, Financial Services), Kevin Wilhelm Vangehr (Associate, M&A), Mark P. Stocker (Associate, Employment Law), Dominik Rietiker (Associate, M&A) and Una Paunovic (Junior Lawyer).